Results 221 to 230 of about 26,872 (292)

No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria. [PDF]

J Pharmacokinet Pharmacodyn
Gao L, Hu Y, Smith N, Uvarov A, Peyret T, Gosselin NH, Kong R.   +6 more
europepmc   +1 more source

Long‐Term Outcomes of Reduced‐Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1294-1305, June 2026.
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean, Carrie Richardson, Anthony J. Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer. [PDF]

J Pharm Health Care Sci
Yokota H, Asahi R, Akamine Y, Kobayashi M, Wakabayashi H, Sakamoto S, Okuda Y, Sato K, Nakayama K, Kikuchi M.   +9 more
europepmc   +1 more source

Radiotherapy and Cardiovascular Disease Survival Risk in Non‐Small Cell Lung Cancer: A Population‐Based Study From the Surveillance, Epidemiology, and End Results Database

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background It is well known that radiotherapy increases the cardiovascular risk of cancer patients, but there are few large‐sample studies with cardiovasular‐specific death as the endpoint in lung cancer patients. Methods Patients aged ≥ 18 years diagnosed with non‐small cell lung cancer were retrospectively enrolled from the Surveillance ...
Li Liu, Chunhui Fan, Wenxin Ren, Mingyi Wen, Cunqi Li, Cuiping Hao, Yian Geng, Liping Zhang   +7 more
wiley   +1 more source

Long QT Syndrome Type 5 With Coexisting KCNE1 and RYR2 Variants: A Diagnostic Ambiguity

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Long QT syndrome (LQTS) predisposes to syncope and sudden cardiac death. Type 5 LQTS, linked to KCNE1 variants, is rare. A teenage female presented with recurrent syncope. ECG showed QTc 485 ms. Genetic testing identified KCNE1 and RYR2 variants. Beta‐blockers and ICD prevented events.
Mohammad Hossein Nikoo, Hossein Fatemian, Amir Hossein Hassani, Mehrdad Rabiee Rad, Sara Mostafavi   +4 more
wiley   +1 more source

Epicardial adipose tissue‐linked leukotriene and cytokine signalling pathways – novel targets for prevention of obesity‐ and diabetes‐linked ventricular arrhythmia

The Journal of Physiology, EarlyView.
Kelly A. Aromolaran, Ademuyiwa S. Aromolaran   +1 more
wiley   +1 more source

From Molecules to Machines: An Integrative Framework Linking Molecular Pathogenesis, Multi‐Factorial Risk, Risk Stratification, Clinical Management, and Artificial Intelligence in QT Prolongation and Sudden Cardiac Death

Clinical Cardiology, Volume 49, Issue 6, June 2026.
An integrative conceptual framework linking the five principal domains addressed in this review. Beginning at the molecular level, loss‐of‐function mutations in KCNQ1 and KCNH2 reduce outward repolarizing currents (IKs and IKr), while gain‐of‐function SCN5A mutations augment late inward sodium current (INa), establishing the genetic substrate for ...
Mojtaba Farjam, Mohammad Hosein Yazdanpanah, Narges Fereydouni   +2 more
wiley   +1 more source

Pacritinib Impact on QT Interval: Results of a Thorough QT Study and Post Hoc Analysis of Prospective Clinical Trial Data

Clinical Pharmacology in Drug Development, Volume 15, Issue 6, June 2026.
Abstract Pacritinib, an inhibitor of JAK2/IRAK1/ACVR1 that is devoid of JAK1 activity, approved for treating myelofibrosis in patients with severe thrombocytopenia, carries a label warning for QT interval prolongation. To evaluate the cardiac safety of pacritinib, a randomized, placebo‐ and active‐controlled, single‐dose thorough QT (TQT) study was ...
Sarah A. Buckley, Suliman Al‐Fayoumi, James P. Dean, Jessica Zhang, Purvi Suthar, Muriel Richard   +5 more
wiley   +1 more source

Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy.
Sanila Mughal, Roshanay Ejaz Awan, Hur Abbas, Zahra Sania, Ashna Habib, Syeda Kaneez Sakina, Amina Mahmud, Mohammed Mahmmoud Fadelallah Eljack   +7 more
wiley   +1 more source